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Abstract 
The most important function of the skin is to form a barrier between the body and the external 
environment. The epidermal barrier prevents transepidermal water loss from the skin, but also 
serves as a barrier to the entry of harmful environmental allergic, toxic or infectious 
substances. Inherited defects in the genes encoding the components of the epidermal barrier 
result in the development of rare genetic disorders, whereas polymorphisms in these genes 
together with environmental factors cause frequent inflammatory skin diseases, such as atopic 
dermatitis. In this review, components of the skin-barrier function will be reviewed with 
special emphasis on how the altered epidermal barrier might be repaired. The different 
strategies to increase the transdermal penetration of drugs is also discussed. 
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INTRODUCTION 
The human skin forms a complex barrier between our bodies and the external environment 
[1,2]. It has been known for a long time that epidermal keratinocytes, making up the 
outermost anatomical structure the epidermis, form an important physical barrier. These cells 
are the bricks in the outer wall of our bodies; they are very strongly attached to one another by 
specialized organelles called tight junctions, and the extracellular space between them is very 
small [3]. This is an important feature of this tissue, as it prevents the loss of water and other 
important chemicals. In addition, when this layer is intact, it makes it very difficult for 
environmental molecules and other harmful invaders (e.g., different microbes) to enter our 
bodies through this strong mechanical boundary.  
The epidermis is also a stratified squamous epithelium in which continuously proliferating 
basal cells in the stratum basale give rise to new keratinocytes that gradually move to the 
upper epidermal layers (stratum granulosum, spinosum and lucidum). During these events the 
cells undergo natural differentiation processes. The keratinocytes become flattened, and their 
cytoplasm is gradually filled with keratin filaments, which are deposited into a matrix 
composed of mostly filaggrin and its breakdown products, to the point of the death of cells. In 
the resulting specialized tissue called stratum corneum (SC), dead keratinocytes (corneocytes) 
are held together by a ‘mortar’ composed of a lipid-enriched extracellular matrix containing 
ceramides (50%), cholesterol (30–35%) and free fatty acids (10–15%) [2,4-6]. These lipids 
are synthesized and released from lamellar bodies at the stratum granulosum – SC-interface, 
and their final processing is done by hydrolytic enzymes also released in parallel with the 
lipid precursors [7]. Together with the corneocytes, they form a dry, completely insoluble and 
nearly impermeable physical structure. 
Apart from the formation of the mechanical or physical barrier, another level of protection 
is the special acidic environment (chemical barrier) established in the first few weeks after 
birth and maintained on our skins throughout life [8]. This acidic ‘mantle’ is important for 
permeability barrier formation and also for antimicrobial defense. It is a result of various 
acidic components of eccrine and sebaceous secretions, proton pumps, and breakdown 
products of processed lamellar body lipids [9].  
Finally, our skin cells are in close connection with a specialized microbial flora, called the 
cutaneous microflora or microbiota [10]. Together with the skin cells, they form an 
immunological barrier, provide efficient protection from harmful pathogenic microorganisms 
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and also, when in a balanced state, help to maintain the integrity and the healthy homeostasis 
of our bodies. Even though their role has long been suggested, the exact cellular and 
molecular mechanism contributing to these functions is just being uncovered. In this paper, 
we summarize what is currently known on this topic. 
The cutaneous barrier is very complex, highly organized and strictly regulated. Its structure 
and function is, in part, genetically programmed. This is proven by the existence of inherited 
factors, mutations and polymorphisms that affect the development, as well as the structure and 
thereby also the function of our skins, often leading to the pathogenesis of various cutaneous 
disorders. 
GENETICS OF THE EPIDERMAL BARRIER AND ASSOCIATED DISEASES 
Large-scale transcriptome profiling of granular keratinocytes revealed genes (n=330) that 
are involved in the formation of the epidermal barrier and in the maintenance of its 
physiological functions [11]. Among the identified genes are several that are implicated in the 
transformation of granular keratinocytes into corneocytes, in lipid metabolism and transport 
or in composition and degradation of cell–cell junctions (summarized in Table 1) [11]. 
Corneocytes contain abundant keratin: approximately 60% of their dry weight is keratin 
proteins [12,13]. In epidermal barrier formation, proteins encoded by the keratin (KRT) 1, 2 
and 10 genes are implicated with pivotal roles [13]. The cornified envelopes of the 
corneocytes contain a large amount of filaggrins, which are associated with keratin 
intermediate filaments and packed into bundles [14,15]. The keratin-filaggrin bundles 
contribute to the insolubility of the epidermal barrier significantly [14,15]. The precursor 
protein of filaggrin, profilaggrin, is encoded by the filaggrin (FLG) gene, which contains 
several tandem filaggrin repeats [16,17]. The segregation of these repeats results in 
polymorphic variation in the size of the FLG gene due to simple allelic differences between 
individuals [16,17]. Another major component of the cornified cell envelope is the protein 
encoded by the loricrin (LOR) gene [18]. The cornified envelope proteins are crosslinked with 
disulfide and gamma-glutamyl-lysine isodipeptide bonds by transglutaminase enzymes such 
as the one encoded by the transglutaminase 1 (TGM1) gene [17]. Other clinically relevant 
genes contributing to the proper functioning of corneocytes are the following: the proteasome 
maturation protein (POMP) gene, encoding a protein pivotal in proteasome assembly [19], 
the excision repair complementing defective in Chinese hamster (ERCC) 2 and 3 genes and 
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the chromosome 7 open reading frame 11 (C7ORF11) gene, encoding proteins important in 
DNA transcription and excision repair [20,21].  
Other genes contribute to epidermal barrier formation either through the metabolism of 
fatty acids, triglycerides and cholesterol or through lipid transport and secretion. Long-chain 
fatty aldehydes are oxidized to fatty acids by the enzyme encoded by the fatty aldehyde 
dehydrogenase (FALDH) gene [22]. Branched fatty acids are broken down by another 
enzyme encoded by the phytanoyl-CoA hydroxylase (PHYH) gene [23,24]. The 12R-
lipoxygenase (ALOX12B) and the epidermis-type lipoxygenase (ALOXE3) genes encode 
enzymes catalyzing the conversion of arachidonic acid to 12R-hydroxyeicosatetraenoic acid 
[25]. The proteins encoded by the cytochrome P450 family 4 subfamily f polypeptide 22 
(CYP4F22), the NIPA-like domain-containing 4 (NIPAL4) and the lipase family member N 
(LIPN) genes also participate in the signaling pathways associated with fatty acids and 
triglycerides [26,27]. The enzymes encoded by the steroid sulfatase (STS), the emopamil-
binding protein (EBP) and the membrane-bound transcription factor protease site 2 
(MBTPS2) genes are implicated in epidermal barrier dysfunction through the metabolism of 
cholesterol [28-30]. The solute carrier family 27 member 4 (SLC27A4) and the ATP-binding 
cassette subfamily A member 12 (ABCA12) genes encode transporter proteins [31,32]. 
Proteins encoded by the adaptor-related protein complex 1 sigma-1 subunit (AP1S1), the 
synaptosomal-associated protein 29-kd (SNAP29) and the vacuolar protein sorting 33 B 
(VPS33B) genes are involved in trafficking [33-35].  
In the development of the epidermal barrier, other genes are also implicated through 
coding either structural components of the cell–cell junctions or proteolytic enzymes 
regulating the digestion of these junctions. The protein encoded by the corneodesmosin 
(CDSN) gene participates in the formation of corneodesmosomes [36], while the proteins 
encoded by the serine protease inhibitor Kazal-type 5 (SPINK5) and the membrane-type 
serine protease 1 (ST14) genes are involved in the degradation of these structures [37,38]. 
These proteolytic enzymes are regulated by inhibitors, such as the cysteine proteinase 
inhibitor encoded by the cystatin A (CTSA) gene [39]. Some of the genes involved in the 
development of other cell–cell junctions, such as the gap junction protein beta (GJB) 2, 3 and 
4 genes and the claudin 1 (CLDN1) gene, also contribute to the proper function of the 
epidermal barrier [40-43].  
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The above reviewed genes have clinical significance, since their mutations result in the 
development of rare, monogenic diseases. Many mutations result in genodermatoses, 
characterized by epidermal barrier dysfunction due to abnormalities in corneocytes, epidermal 
lipids or cell–cell junctions. Disease-causing genetic variations of the genes implicated in the 
development of corneocytes are associated with high clinical heterogeneity. TGM1 mutations 
have been linked to several clinical variants of autosomal recessive congenital ichthyosis, 
such as the well known lamellar ichthyosis phenotype and the self-healing collodion baby 
phenotype, in which the condition is present at birth, but spontaneously improves [44,45]. A 
very rare form of this latter clinical variant is the acral self-healing collodion baby, in which 
the membrane is located on the extremities only [46]. TGM1 mutations can also lead to 
development of bathing suit ichthyosis, another clinical form of autosomal recessive 
congenital ichthyosis, in which scaling is pronounced in the bathing suit area and is less 
pronounced on extremities [47]. FLG mutations have been associated with the development of 
the most common and mildest form of hereditary non-syndromic ichthyosis, ichthyosis 
vulgaris [17,48]. Of note, among common diseases, FLG variations are major predisposing 
factors for atopic dermatitis [49]. KRT1 mutations impairing the interaction and network 
formation of intermediate filaments are frequently associated with epidermolytic 
hyperkeratosis [50]. KRT1 mutations are also involved in the development of palmoplantar 
keratodermas [51]. KRT2 and KRT10 disease-causing genetic variations can also be 
associated with epidermolytic hyperkeratosis [52]. KRT10 mutations can also contribute to 
ichthyosis with confetti, a rare form of ichthyosis with a reticulated pattern [53]. LOR 
mutations result in loricrin keratoderma [18]. POMP causative variants are associated with 
keratosis linearis with ichthyosis congenita and sclerosing keratoderma [19]. ERCC2, ERCC3 
and C7ORF11 mutations are pivotal in trichothiodystrophy; additionally, ERCC2 and ERCC3 
causative variants are implicated in xeroderma pigmentosum [20,21].  
Causative variations of the genes linked with abnormal lipid metabolism and transport and, 
thus consequently epidermal barrier dysfunction, can contribute to the development of clinical 
variants of the same disease with overlapping symptoms, since ALOX12B, ALOXE3, 
CYP4F22, NIPAL4, ABCA12 and LIPN mutations are frequently associated with the different 
clinical forms of autosomal recessive congenital ichthyosis [23,25-27,32]. FALDH mutations 
result in Sjögren-Larsson syndrome [22]. PHYH causative variants are associated with 
Refsum syndrome [24]. STS disease-causing variants contribute to the development of X-
linked ichthyosis [28]. EBP mutations are linked with Conradi-Hünermann-Happle or MEND 
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syndromes [29,54]. MBTPS2 mutations can lead to the development of ichthyosis follicularis-
alopecia-photophobia syndrome, keratosis follicularis spinulosa decalvans and Olmsted 
syndrome, characterized by mutilating palmoplantar keratoderma with periorificial keratotic 
plaques [30]. SLC27A4 mutations lead to ichthyosis prematurity syndrome [31].  
Disease-causing variants of genes implicated in trafficking can lead to severe multisystem 
disorders with overlapping clinical features: AP1S1 mutations cause the mental retardation, 
enteropathy, deafness, neuropathy, ichthyosis, and palmoplantar keratoderma (MEDNIK) 
disorder, whereas SNAP29 mutations are associated with cerebral dysgenesis, neuropathy, 
ichthyosis, and palmoplantar keratoderma (CEDNIK) [34,35]. VPS33B mutations contribute 
to development of arthrogryposis-renal dysfunction-cholestasis syndrome [33]. 
Mutations of genes implicated in the formation and degradation of cell–cell junctions and, 
thus consequently epidermal barrier dysfunction, are associated with high clinical 
heterogeneity. CDSN mutations can lead to the development of epidermolysis bullosa 
simplex, hypotrichosis simplex and peeling skin syndrome [36]. CTSA mutations are also 
implicated in peeling skin syndrome [55]. SPINK5 causative variants are associated with 
Netherton syndrome and atopy [38]. ST14 disease-causing variants result in autosomal 
recessive congenital ichthyosis [37]. Since GJB2, 3 and 4 genes are expressed in a wide range 
of organs and tissues, their mutations are implicated in numerous diseases, such as 
erythrokeratodermia variabilis, keratitis-ichthyosis-deafness syndrome, palmoplantar 
keratodermas, ectodermal dysplasia and deafness syndromes [40,42,43]. CLDN1 mutations 
contribute to the development of neonatal sclerosing cholangitis associated with ichthyosis 
syndrome [39]. The functional classification of the diseases featuring epidermal barrier 
dysfunction gives insight into the functional relationships among these entities and also 
highlights the significant clinical heterogeneity of these diseases.  
 
DEVELOPMENT OF THE EPIDERMAL BARRIER 
 
All of the anatomic elements of the skin are fully developed by weeks 22 to 24 of 
gestation, whereas functional and biochemical maturity requires a much longer time. At 
gestational week 24, the epidermis is immature, with the SC consisting of only one to two cell 
layers [56,57]. In preterm infants, the full thickness of the skin (0.9 mm) is much less than in 
term infants (1.2 mm), and this is also the case for the thickness of the epidermis and SC 
[56,57]. The uppermost layer of the epidermis, the SC, which consists of corneocytes, plays a 
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considerable role in the barrier function of the skin [58-60]. The physical barrier of the skin 
represented by the SC is mainly determined by its thickness and integrity. By weeks 33 to 34 
of gestation, the SC has attained structural and functional maturity, although the active 
adaptation and maturation processes continue after birth [56,57,59,60]. Changes in skin pH, 
development of the protecting acid envelope and continuous colonization by cutaneous 
microbiota play a crucial role in the adaptation process. [56-59] 
The basic structural differences between the skin of a preterm neonate, a term neonate and 
an adult are of considerable importance in clinical practice. The structure of the skin of a full-
term neonate is similar to that of an adult, but it is much thinner and more vulnerable [60,61]. 
The skin of a term neonate is structurally and functionally more ready to adapt to an air 
environment than the skin of a premature infant, which is in homeostasis with a fluid 
environment. After delivery, premature skin matures rapidly over 2 to 8 weeks, but this 
process takes significantly longer for extremely premature neonates [56,57,60]. 
In premature infants, the structural and functional maturation of the epidermis accelerates 
significantly, taking approximately 2 weeks after birth. As a consequence of this accelerated 
maturation period, the epidermis of an extremely premature infant undergoes a dramatic 
development during these 2 weeks, resulting in markedly decreased transepidermal water loss 
(TEWL) and a reduced possibility to absorb various toxic agents [58,60]. Preterm neonates 
are obviously highly vulnerable during this 2-week period. Septic complications occur mainly 
in the first few days or the first 2 weeks of life and are the most common cause of mortality in 
this special population. The compromised epidermal barrier function results in an enhanced 
susceptibility to severe invasive infections, high rates of TEWL, thermal instability, 
electrolyte imbalance, increased percutaneous absorption of chemicals and drugs, and easily 
induced skin traumas; these clinical complications are relevant determinants of the high 
morbidity and mortality rates for preterm infants [56-58,61]. In extremely premature infants, 
the TEWL can be as much as 10–15 times higher than in full-term infants; a neonate born at 
24 weeks of gestation can lose 13% body weight on the first day of life as a consequence of 
the high fluid loss due to the virtual absence of the epidermal barrier [57,58,60]. TEWL is 
influenced by the gestational age of the infant, body region, and humidity of the environment. 
TEWL and percutaneous absorption are inversely proportional to gestational age, and SC 
hydration increases with age [56,57,60]. 
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Another anatomical-structural difference between premature and mature infants is that the 
dermoepidermal junction is flat and anchoring fibrils, anchoring filaments and 
hemidesmosomes are fewer and smaller in preterm neonates, which results in a decreased 
resistance to shear forces. Due to the immaturity of the dermoepidermal junction, the 
epidermis and dermis can easily separate from each other; moreover, bullae can develop much 
more easily after thermal or mechanical impact. The skin is therefore fragile and prone to 
inadvertent cutaneous injury [56,57,61]. The dermis is also thinner, less collagenized and 
more gelatinous, and this gives rise to an increased risk of oedema, resulting in the risk of 
ischaemic injury. Moreover, in consequence of the thin layer of subcutaneous fat and 
immature eccrine glands, premature infants have a compromised thermoregulatory capability 
[56,57]. 
 
IMPAIRED EPIDERMAL BARRIER IN INFLAMMATORY SKIN DISEASES 
 
Defective epidermal barrier function is the main feature of the most common inflammatory 
skin disorders, such as atopic dermatitis and, to a lesser extent, psoriasis [62,63]. Atopic 
dermatitis is a chronic skin disease affecting up to 20% of the pediatric population in 
developed countries. The main pathogenetic factor of atopic dermatitis is skin barrier damage, 
where the crucial predisposing factors are mutations and intragenic variations in the copy 
number of FLG monomers [49,64]. However, recent data suggest that the inflammatory 
cytokines and chemokine milieu in atopic skin can also down-regulate FLG gene expression, 
resulting in filaggrin deficiency and impaired epidermal barrier. These data suggest that 
severe skin inflammation and filaggrin mutations similarly alter the skin barrier [65,66]. As 
inherited or acquired barrier defect is the major pathogenic factor of the disease, restoration of 
the impaired barrier is the key therapeutic approach in the treatment of atopic dermatitis 
(Figure 1).  
Psoriasis is also a multifactorial inflammatory skin disease, affecting approximately 2–3% 
of the population. Genetic and environmental factors result in impaired skin barrier in 
psoriatic lesions, and this danger signal might contribute to the hyperproliferation and 
inflammatory cytokine production of keratinocytes [63]. As damage to the skin barrier results 
in further inflammatory cytokine production, barrier restoring therapy is an important strategy 
in the management of chronic inflammatory skin diseases. 
 
BARRIER RESTORING THERAPIES 
 10 
 
 
Moisturizers 
Xerosis, or dry skin, is frequently the most apparent sign indicating impairment of the 
skin’s barrier function. Dry skin can be caused by altered environmental factors (e.g., seasons, 
climate, excessive bathing, etc.) or endogenous factors (e.g., aging, deficiencies in the skin’s 
natural moisturizing factor (NMF), barrier lipid content, etc.) [67-69]. Moisturizers are widely 
applied to treat dry skin caused by different factors and are based on several formulations 
which contribute to barrier repair, reduction of TEWL or aesthetic improvement of irritated 
skin [67]. Moisturizers, which can be prescription but are more often over-the-counter 
formulations, belong to the standard therapy of atopic dermatitis [70] and may also be useful 
in the treatment of irritant contact dermatitis. Three main classes of moisturizers can be 
distinguished: emollients, occlusives and humectants (Table 2).  
Emollients are oily substances which are designed to bring small lipid droplets into the 
cracks between desquamating corneocytes in dry skin, thereby increasing the softness, 
flexibility and smoothness of the skin [71]. Containing oils and lipids (e.g., different fatty 
acids from palm oil, coconut oil and wool fat) [72], emollients are designed to maintain 
healthy skin conditions rather than to repair damaged skin or have long-term effects [67]. 
Occlusives are also lipophilic preparations which provide a hydrophobic barrier on the skin 
surface to reduce TEWL. Moreover, this film protects from external irritants. Thus, these 
preparations are applied to dry or damaged skin because they promote barrier repair due to the 
mentioned mechanisms. Petrolatum is one of the most effective occlusives. Lanolin, mineral 
oil, beeswax, soybean oil, paraffin and propylene glycol are also used as occlusives. Silicones 
(e.g., dimethicone, cyclomethicone) are relatively new hypoallergenic occlusives. A 
disadvantage of occlusive preparations is that they can be aesthetically less pleasing than oil-
in-water emulsions [67,68,71]. 
Humectant-based moisturizers are frequently used to treat dry skin. These preparations, 
which contain inter alia polyols (e.g., glycerol, sorbitol and mannitol), provide hydrating 
effects to the skin by attracting and binding water from the deep epidermis and the 
environment. Compared to other formulations, they are absorbed faster and therefore are 
aesthetically better, promoting patient compliance [67,73]. Polyols may provide protection 
against irritation via different pathways. Certain advantageous effects of polyols originate in 
their chemical structure. It is known that glycerol, which is the most frequent polyol in 
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dermatological topical preparations, diffuses into the SC and retains water in the skin. Further, 
glycerol may interact with SC lipid structures and proteins, altering their water-binding and/or 
hydrophilic properties [74]. The hydrating effect of glycerol has been shown in a number of 
animal experiments and human studies [75]. Furthermore, glycerol promotes skin barrier 
function [76,77]. This effect may be explained by the moisturizing property of glycerol, since 
an inverse relationship between TEWL and SC hydration is known [1]. Moreover, glycerol 
reduces the density and the average radius of aqueous pores in SC, hereby decreasing the 
ability of irritant agents to penetrate the SC [78]. In addition to moisturizing and providing 
barrier restoring potential, glycerol improves mechanical properties of the skin [79]). There is 
a correlation between SC hydration and skin mechanical properties [80]. The skin friction 
coefficient also shows positive correlation with SC hydration [81]. Another study suggests 
that the effects of glycerol on mechanical parameters may be independent of its hydrating 
ability [79]. Effects of glycerol have been extensively studied; however less information is 
available for other polyols. Previously, we found that xylitol also suppresses skin irritation 
[65]. Mannitol alone had no effect on skin irritation [65], but combined application of 
mannitol and hyaluronic acid increased skin hydration and elasticity [82]. In contrast, sorbitol 
was found to improve barrier function and act as a moisturizer [83]. 
In addition to inducing physical or chemical alterations, polyols might also change gene 
expression. In vitro experiments have shown that glycerol decreases the expression of human 
leukocyte antigen DR (HLA-DR), thereby reducing inflammation, whereas xylitol increases 
the expression of filaggrin [84]. Filaggrin, as a source of NMF and in other ways, contributes 
to hydration and homeostasis of the skin [85]. Recent animal experiments have revealed that 
both glycerol and xylitol decrease the expression of tumor necrosis factor alpha (TNF-α) and 
interleukin 1-beta (IL-1ß) in sodium lauryl sulphate (SLS) induced acute irritation [86]. In this 
experimental setup, application of polyols inhibited the SLS-induced elevation of TEWL, 
moderated the irritant-induced increase in dermal blood flow and prevented accumulation of 
lymphocytes and neutrophil granulocytes. Further, it was found that both glycerol and xylitol 
hamper the penetration of irritant agents [86]. Thus, polyols exert anti-irritant effects via 
different pathways.  
Other important factors are the antimicrobial effects of polyols. Barrier damage leads to 
changes in skin flora [87]; therefore, patients with irritant or atopic dermatitis may need 
protection against bacterial colonization. Glycerol in 85% concentration was found to have 
antimicrobial effects [88]. Additionally, glycerol possesses virucidal properties [89]. 
 12 
 
However, Gram-positive species are less susceptible to glycerol than Gram-negatives. Xylitol, 
combined with farnesol [90] or with glycerol [91] effectively eliminates Gram-positive 
bacteria, and its effective concentration was found to be 5% in both studies. Hence, 
application of polyols may prevent both irritation and bacterial colonization of the skin 
(Figure 2).  
A new generation of moisturizers could contain special ingredients which supply normal 
skin components. Ceramides, with cholesterol and fatty acids, belong to the main lipid groups 
of SC and play a pivotal role in barrier function [92]. NMF, originating from the catabolism 
of filaggrin, maintains adequate SC hydration [85]. NMF is a mixture of free amino acids, 
inorganic salts, sugars, lactic acid and urea. It should be noted that that a combination of 
different types of moisturizers can be advantageous. Humectants can be combined with 
occlusive components when applied to skin with a defective barrier to attract water and to 
prevent its evaporation [93]. Ceramides, pseudoceramides and NMFs have been studied and 
added to commercial moisturizers to hydrate skin and improve barrier function [94]. 
 
Anti-inflammatory therapies 
Inflammation in the skin results in epidermal barrier damage similar to that present in 
patients with filaggrin mutation, suggesting that anti-inflammatory treatment might affect the 
barrier functions of the skin. 
Topical glucocorticosteroids  
Topical corticosteroids (TCS) have been widely used for the treatment of inflammatory 
skin disorders in dermatological practice for decades. Corticosteroids have numerous anti-
inflammatory, antiproliferative and immunosuppressive effects, and topical medications are 
available in different formulations with a wide range of potency. TCS remain the mainstay 
and gold standard for the treatment of acute inflammatory symptoms in AD and can achieve 
excellent results in both short-term and proactive maintenance therapy [57,95-98]. Topical 
steroids result in rapid improvement of skin inflammation and pruritus, but have opposing 
effects on barrier functions [95,99,100]. Positive effects of topical corticosteroids on the skin 
barrier include the increase of SC hydration, decrease of TEWL, and normalization of 
filaggrin and loricrin expression [95,100,101]. However, human studies and animal models 
demonstrated that long-term application of local glucocorticoids resulted in significant 
impairment of epidermal barrier function and homeostasis. Morphological, physicochemical 
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and functional alterations include decreased epidermal proliferation and differentiation, 
inhibition of the synthesis of epidermal barrier lipids and antimicrobial peptide formation, 
decrease of lamellar body formation, delay of barrier recovery, and reduction of the integrity 
and cohesion of SC; additionally, topical steroids also have negative effects on epidermal 
immune cells [95,99,100]. The application of topical steroids in special, advanced vehicle 
formulations and adequate adjunctive barrier repair therapy with emollients and moisturizers 
can significantly reduce these negative effects and promote the maintenance of epidermal 
barrier functions [95,99]. There are also several well known cutaneous side-effects of 
prolonged use of topical glucocorticosteroids, such as atrophy, striae, purpura, telangiectasias, 
hypertrichosis, alopecia, hyperpigmentation and impairment of wound healing; these effects 
are mostly preventable with rational application of the medications [57,95,102].  
Topical calcineurin inhibitors 
The introduction of topical calcineurin inhibitors (tacrolimus and pimecrolimus) resulted in 
a significant breakthrough in the anti-inflammatory treatment of atopic dermatitis. These 
macrolactam derivatives have more specific immunomodulatory and anti-inflammatory 
effects than glucocorticoids, acting by inhibition of proinflammatory cytokine expression in 
T-lymphocytes and other inflammatory cells. In contrast to topical steroids, pimecrolimus and 
tacrolimus do not induce skin atrophy, and thus calcineurin inhibitors are suitable for long-
term maintenance therapy even on the head, neck and intertriginous areas [96-98]. Topical 
calcineurin inhibitors influence the epidermal barrier function in several ways, and a 
beneficial effect is observed by improving SC hydration and reducing TEWL [100,103]. 
However, local calcineurin inhibitors might also have negative impacts on epidermal barrier 
function by decreasing epidermal lipid synthesis, lamellar body secretion and antimicrobial 
peptide expression and production. The calcineurin inhibitor-induced impairment of the 
permeability and antimicrobial barrier could be prevented by emollient treatment [103]. 
 
TRANSDERMAL DRUG DELIVERY 
 
Barrier function provided by the SC is indispensable to avoid the loss of water and to 
provide protection against irritant and causative agents. However, the same barrier often 
hampers transdermal drug delivery. This method is a useful alternative pathway for 
therapeutic agents that are prone to decompose in the gastrointestinal tract and permits the 
achievement of relatively high local drug concentrations without systemic side effects. Due to 
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the epidermal barrier, different techniques are required for the enhancement of skin 
permeability. Methods modifying the barrier properties can be passive or active. Passive 
methods include the influencing of drug and vehicle interactions and optimization of 
formulation to modify SC structure [104]. A widely used passive method is the application of 
chemical penetration enhancers that facilitate drug permeation across the skin. Several 
compounds are able to contribute to a better penetration, e.g., alcohols, amides, esters, ether 
alcohols, fatty acids, glycols, pyrrolidones, sulfoxides, surfactants and terpenes [105]. 
Penetration enhancers have different mechanisms of action, e.g., increasing the fluidity of the 
SC lipid bilayers, interaction with intercellular proteins, disruption or extraction of 
intercellular lipids, increasing the drug’s thermodynamic activity or increasing SC hydration 
[106,107]. Their primary disadvantage is that chemical penetration enhancers often evoke 
skin irritation (local inflammation) and their efficacy is relatively low [108-110].  
Another passive method is the use of special carrier systems to increase drug flux into and 
through the skin. These carrier systems can be nanoparticles and nanofibers which can be 
used to enhance solubility of highly hydrophobic drugs, provide controlled and sustained 
release of drugs, increase the stability of therapeutic agents, and deliver higher drug 
concentrations to target areas. Several types of nanoparticles are available: natural polymeric 
(e.g., chitosan and albumin), synthetic polymeric (e.g., tyrosine-derived polymeric 
nanospheres, poly(lactic-co-glycolic acid)), lipid-based (liposomes, solid-lipid), metallic and 
silica, as well as dendrimers. However, only a few of these techniques have been translated 
into clinically used products so far. Hence, further clinical studies are needed [111]. 
Furthermore, prodrugs can also be used. Prodrugs are synthesized by a chemical modification 
of a drug for more optimal physicochemical and/or pharmacokinetic properties. After 
delivery, the prodrug is cleaved by enzymes leading to the formation of the parent drug [112]. 
Hyaluronic acid is an effective moisturizer, but its penetration ability is poor. However, cross-
linking the molecule results in better penetration through human epidermis and living animal 
skin [113].  
Active, physical methods involve several different techniques (e.g., use of electrical forces, 
lasers, ultrasound and microneedles). Electrical force can be used as iontophoresis or 
electroporation. The latter is a promising method which temporarily creates aqueous pores in 
cell membranes using electric pulses of high voltage and short duration. Electroporation 
successfully enhances skin permeability for molecules with different lipophilicities and sizes, 
including high-molecular-weight biopharmaceuticals. Nevertheless, the relationship between 
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electroporation and skin irritation should be clarified. Since high voltage pulses are used, it is 
important to ensure that there are no harmful effects in the skin [114].  
Lasers can also be used to assist drug delivery. By means of laser, fractional 
photothermolysis can be performed: i.e., multiple vertical columns of tissue in the SC and 
underlying layer are thermally destroyed to create unimpeded channels. On treated skin, the 
channels and the surrounding thermally coagulated tissue enhance penetration while the 
untreated area serves as a reservoir for regeneration [115].  
Ultrasound is able to affect skin permeability. Penetration of cationic, neutral and anionic 
particles and also those of gold nanoparticles and dendrimers are enabled by ultrasound [116].  
Microneedle devices are composed of arrays of micron-size needles. When applied to the skin 
surface, they bypass the SC without stimulating dermal nerves. The holes created by the 
needles can be used to deliver drugs on the skin surface to the dermal microcirculation [117]. 
These techniques may also be combined to increase efficacy and to reduce side effects. 
 
THE EPIDERMAL BARRIER: FUTURE PERSPECTIVES 
 
Understanding the molecular mechanism of epidermal barrier function and the inherited 
factors leading to genetic diseases resulting in skin barrier defects might pave the way for 
better treatments not only for rare hereditary, but also for common multifactorial 
inflammatory skin diseases. Because of the importance of the intact barrier for the healthy 
state of our bodies, maintenance and restoration when it becomes compromised is vital.  
Transdermal drug delivery represents an attractive opportunity for the administration of 
different drugs. Scientific and technological advances by targeted disruption of the epidermal 
barrier resulting in better transdermal penetration of various treatments will have a 
widespread impact in medicine. 
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Tables 
Table 1. Genes involved in the development of the epidermal barrier and their associated diseases.  
 Genes involved in 
the formation of 
the epidermal 
barrier 
Associated diseases References 
E
n
co
d
in
g
 c
o
m
p
o
n
en
ts
 o
f 
k
er
a
ti
n
o
cy
te
s 
a
n
d
 c
o
rn
eo
cy
te
s 
KRT 1 Epidermolytic hyperkeratosis, palmoplantar 
keratodermas 
[12, 13, 50] 
 KRT2  Epidermolytic hyperkeratosis [12, 13, 52] 
KRT10 Epidermolytic hyperkeratosis, ichthyosis with 
confetti 
[12, 13, 52,53] 
FLG Ichthyosis vulgaris, atopic dermatitis [14,15, 16, 
17,48,49] 
LOR Loricrin keratoderma [18] 
TGM1 Autosomal recessive congenital ichthyosis [17,44,45,47] 
POMP Keratosis linearis with ichthyosis congenita and 
sclerosing keratoderma 
[19] 
ERCC2 Trichothiodystrophy [20,21] 
ERCC3 Trichothiodystrophy [20,21] 
C7ORF11 Trichothiodystrophy [20,21] 
E
n
co
d
in
g
 c
o
m
p
o
n
en
ts
 o
f 
li
p
id
 m
et
a
b
o
li
sm
 
FALDH Sjögren-Larsson syndrome [22] 
PHYH Refsum syndrome [23,24] 
ALOX12B Autosomal recessive congenital ichthyosis [25] 
ALOXE3 Autosomal recessive congenital ichthyosis [25] 
CYP4F22 Autosomal recessive congenital ichthyosis [26,27] 
NIPAL4 Autosomal recessive congenital ichthyosis [26,27] 
LIPN Autosomal recessive congenital ichthyosis [26,27] 
STS X-linked ichthyosis [28,29,30] 
EBP Conradi-Hünermann-Happle syndrome, MEND 
syndrome 
[28,29,30,54] 
MBTPS2 Ichthyosis follicularis-alopecia-photophobia 
syndrome, keratosis follicularis spinulosa decalvans, 
olmsted syndrome 
[28,29,30] 
SLC27A4 Ichthyosis prematurity syndrome [31,32] 
ABCA12 Autosomal recessive congenital ichthyosis [31,32] 
AP1S1 MEDNIK syndrome [33,34,35] 
SNAP29 CEDNIK syndrome [33,34,35] 
VPS33B Arthrogryposis-renal dysfunction-cholestasis 
syndrome 
[33,34,35] 
E
n
co
d
in
g
 c
o
m
p
o
n
en
ts
 o
f 
ce
ll
–
ce
ll
 j
u
n
ct
io
n
s 
CDSN Epidermolysis bullosa simplex, hypotrichosis 
simplex, peeling skin syndrome 
[36] 
SPINK5 Netherton syndrome [37,38] 
ST14 Autosomal recessive congenital ichthyosis [37,38] 
CTSA Peeling skin syndrome [39,55] 
GJB2 Erythrokeratodermia variabilis, keratitis-ichthyosis-
deafness syndrome, palmoplantar keratodermas, 
ectodermal dysplasias, deafness syndromes  
[40,41,42,43] 
GJB3 Erythrokeratodermia variabilis, deafness syndromes [40,41,42,43] 
GJB4 Erythrokeratodermia variabilis [40,41,42,43] 
CLDN1 Neonatal sclerosing cholangitis with ichthyosis 
syndrome 
[40,41,42,43] 
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Table 2. Main classes of moisturizers. 
Type Characteristics Examples 
Emollients Smoothing and softening 
skin 
Oils, lipids (e.g., stearic, 
linoleic, linolenic, oleic, 
lauryl acids) 
Occlusives Providing hydrophobic 
barrier which protects from 
loss of water and external 
irritants 
Petrolatum, lanolin, mineral 
oil, beeswax, propylene 
glycol, silicones, etc. 
Humectants Attracting and binding water 
in SC 
Glycerol, sorbitol, urea, 
lactic acid, amino acids, etc.  
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Figure 1. The pathogenesis of atopic dermatitis. The interaction of genetic, environmental 
and immunologic factors create a permissive environment for the initiation and progression of 
the disease. Through the impared epidermal barrier penetration of external allergens, microbes 
and microbial compounds are enhanced, creating immune activation and subsequent 
inflammation. 
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Figure 2. Effects of polyols on the skin. 
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